Synergy CHC Corp. (SNYR) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
Synergy CHC Corp. is a consumer health care company focused on building a portfolio of consumer product brands, primarily in the nutraceutical sector (e.g., FOCUSfactor, Flat Tummy). The company operates as a non-accelerated filer and smaller reporting company. This filing covers the quarterly period ended September 30, 2025, and the nine-month period ended September 30, 2025, compared to the same periods in 2024.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2024 |
|---|---|---|---|
| Total Revenue | $8,010,112 | $24,315,642 | $24,563,036 |
| Gross Profit | $5,680,816 (71% Margin) | $18,083,441 (74% Margin) | $17,141,106 (70% Margin) |
| Net Income | $125,327 | $2,474,827 | $2,019,309 |
| EBITDA (Non-GAAP) | $1,311,570 | $7,095,207 | $4,793,035 |
| Cash and Cash Equivalents | $1,006,489 | $1,006,489 | $687,920 (Dec 31, 2024) |
| Total Debt (Notes Payable) | $25,113,177 | $25,113,177 | $27,515,346 (Dec 31, 2024) |
| Stockholders' Deficit | $(8,252,347) | $(8,252,347) | $(16,631,343) (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Composition: While total revenue for the nine months remained relatively flat compared to 2024, the mix shifted significantly. Product sales decreased by approximately $3.1 million due to a non-recurring sell-in to a customer in 2024. This was offset by $2.9 million in license revenue recognized in 2025.
- Profitability: Net income for the nine months increased by 22% to $2.47 million, driven largely by a $2.15 million gain on the settlement of notes payable. Operating income increased to $4.85 million (nine months) from $4.44 million in the prior year.
- Debt Restructuring: The company significantly restructured its debt profile. It repaid a $10 million shareholder loan and settled other supplier loans, resulting in the aforementioned gain. Concurrently, it secured a new $17.5 million term loan in May 2025, increasing long-term debt obligations.
- Capital Raise: In August 2025, the company completed an IPO, issuing 1.75 million shares and raising net proceeds of approximately $3.88 million.
- Operating Cash Flow: Net cash used in operating activities increased to $3.21 million for the nine months ended Sept 30, 2025, compared to $1.38 million in the prior year, primarily due to increases in prepaid expenses and accounts receivable.
Guidance, Outlook, and Risks
- Outlook: Management intends to grow organically by launching new products (specifically ready-to-drink beverages for FOCUSfactor) and expanding into new markets. The company is also evaluating strategic acquisitions.
- Liquidity: As of September 30, 2025, the company held $1.01 million in cash and $100,000 in restricted cash. The new $17.5 million credit agreement includes covenants requiring a maximum consolidated senior net leverage ratio (starting at 3.25:1.00) and a fixed charge coverage ratio of 1.20.
- Risks and Contingencies:
- Customer Concentration: Three customers accounted for approximately 80% of net revenue for the nine months ended September 30, 2025.
- Related Party Transactions: Significant transactions exist with the CEO and related entities, including a $4.4 million loan receivable from a related party and prepaid consulting fees.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of the end of the period.
- Tax Position: The company has a 100% valuation allowance on deferred tax assets due to uncertainty regarding the realization of net operating loss carryforwards.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new $17.5 million loan covenants (leverage and coverage ratios) given the high interest expense ($4.36 million for nine months).
- Revenue Quality: Assess the sustainability of the $2.9 million license revenue and the reasons for the decline in core product sales.
- Related Party Exposure: Review the terms and repayment likelihood of the $4.4 million loan receivable from a related party and the nature of prepaid consulting fees to the CEO.
- Internal Controls: Investigate the specific deficiencies leading to the conclusion that disclosure controls were ineffective.
- Cash Burn: Monitor the negative operating cash flow of $3.2 million against the current cash balance of ~$1.1 million to assess runway without further financing.